The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Cell-based therapeutic strategies for multiple sclerosis
Open accessAbstract
The availability of multiple disease-modifying medications with regulatory approval to treat multiple sclerosis illustrates the substantial progress made in therapy of the disease. However, all are only partially effective in preventing inflammatory tissue damage in the central nervous system and none directly promotes repair. Cell-based therapies, including immunoablation followed by autologous haematopoietic stem cell transplantation, mesenchymal and related stem cell transplantation, pharmacologic manipulation of endogenous stem cells to enhance their reparative capabilities, and transplantation of oligodendrocyte progenitor cells, have generated substantial interest as novel therapeutic strategies for immune modulation, neuroprotection, or repair of the damaged central nervous system in multiple sclerosis. Each approach has potential advantages but also safety concerns and unresolved questions. Moreover, clinical trials of cell-based therapies present several unique methodological and ethical issues. We summarize here the status of cell-based therapies to treat multiple sclerosis and make consensus recommendations for future research and clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
A perivascular origin for mesenchymal stem cells in multiple human organs
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.003 · Cited by 3,991
Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005) · Blood · doi:10.1182/blood-2005-05-2004 · Cited by 2,969
Lee, R. H., Pulin, A. A., Seo, M. J., Kota, D. J., Ylostalo, J., Larson, B. L., Semprun-Prieto, L., Delafontaine, P., & Prockop, D. J. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.05.003 · Cited by 1,898 · cited 1×
“Emerging evidence also suggests potential immune-modulating effects result from the interaction of MSCs and immune cells in the lung (Lee et al., 2009; Odoardi et al., 2012).”
BackgroundMultiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Somatic coding mutations in human induced pluripotent stem cells
Gore, A., Li, Z., Fung, H.-L., Young, J. E., Agarwal, S., Antosiewicz-Bourget, J., Canto, I., Giorgetti, A., Israel, M. A., Kiskinis, E., et al. (2011) · Nature · doi:10.1038/nature09805 · Cited by 1,273
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991
Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation
Prockop, D. J., & Youn Oh, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.211 · Cited by 816 · cited 1×
“Suppression of inflammation, immune modulation Bone marrow-derived cells have pronounced immune-modulating properties (Prockop and Oh, 2012), affecting both innate and adaptive immune systems.”
BackgroundWindrem, M. S., Nunes, M. C., Rashbaum, W. K., Schwartz, T. H., Goodman, R. A., McKhann, G., Roy, N. S., & Goldman, S. A. (2004) · Nature Medicine · doi:10.1038/nm974 · Cited by 451
Self-citationDrug-based modulation of endogenous stem cells promotes functional remyelination in vivo
Najm, F. J., Madhavan, M., Zaremba, A., Shick, E., Karl, R. T., Factor, D. C., Miller, T. E., Nevin, Z. S., Kantor, C., Sargent, A., et al. (2015) · Nature · doi:10.1038/nature14335 · Cited by 424
Self-citationLi, C.-Y., Wu, X.-Y., Tong, J.-B., Yang, X.-X., Zhao, J.-L., Zheng, Q.-F., Zhao, G.-B., & Ma, Z.-J. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0066-5 · Cited by 410 · cited 1×
“The question of whether MSCs from different tissue sources are identical in all properties is not wholly resolved (Strioga et al., 2012; Li et al., 2015).”
BackgroundFrançois, M., Copland, I. B., Yuan, S., Romieu-Mourez, R., Waller, E. K., & Galipeau, J. (2012) · Cytotherapy · doi:10.3109/14653249.2011.623691 · Cited by 375 · cited 1×
“Issues of donor variance, immunogenicity, culture expansion, epigenetic reprogramming, senescence, and (perhaps particularly) cryopreservation and thawing (Francois et al., 2012; Chinnadurai et al., 2014, 2016) may have contributed to these negative results.”
BackgroundSelf-citationCohen, J. A., Reingold, S. C., Polman, C. H., & Wolinsky, J. S. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70059-5 · Cited by 233 · cited 1×
“…outcomes most often used in multiple sclerosis clinical trials are relapses, confirmed worsening of disability measured by the Expanded Disability Status Scale (EDSS) or Multiple Sclerosis Functional Composite, MRI lesion activity and burden, and normalized whole brain volume (Cohen et al., 2012).”
Self-citationCortical remyelination: A new target for repair therapies in multiple sclerosis
Chang, A., Staugaitis, S. M., Dutta, R., Batt, C. E., Easley, K. E., Chomyk, A. M., Yong, V. W., Fox, R. J., Kidd, G. J., & Trapp, B. D. (2012) · Annals of Neurology · doi:10.1002/ana.23693 · Cited by 216 · cited 1×
“Although it is possible these interventions directly stimulate repair to some degree, it is more likely they unmask intrinsic repair mechanisms by effectively suppressing ongoing inflammatory damage (Chang et al., 2002, 2008, 2012).”
BackgroundChinnadurai, R., Garcia, M. A., Sakurai, Y., Lam, W. A., Kirk, A. D., Galipeau, J., & Copland, I. B. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.05.003 · Cited by 139 · cited 1×
“Issues of donor variance, immunogenicity, culture expansion, epigenetic reprogramming, senescence, and (perhaps particularly) cryopreservation and thawing (Francois et al., 2012; Chinnadurai et al., 2014, 2016) may have contributed to these negative results.”
BackgroundSelf-citationLaterza, C., Merlini, A., De Feo, D., Ruffini, F., Menon, R., Onorati, M., Fredrickx, E., Muzio, L., Lombardo, A., Comi, G., et al. (2013) · Nature Communications · doi:10.1038/ncomms3597 · Cited by 121
Shen, L. H., Xin, H., Li, Y., Zhang, R. L., Cui, Y., Zhang, L., Lu, M., Zhang, Z. G., & Chopp, M. (2011) · Stroke · doi:10.1161/strokeaha.110.593863 · Cited by 51
Hampton, D. W., Serio, A., Pryce, G., Al-Izki, S., Franklin, R. J., Giovannoni, G., Baker, D., & Chandran, S. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-84 · Cited by 34
Cited by
Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,797
Self-citationTreatment of multiple sclerosis — success from bench to bedside
Tintore, M., Vidal-Jordana, A., & Sastre-Garriga, J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0082-z · Cited by 343
Mesenchymal stromal cell apoptosis is required for their therapeutic function
Pang, S. H. M., D’Rozario, J., Mendonca, S., Bhuvan, T., Payne, N. L., Zheng, D., Hisana, A., Wallis, G., Barugahare, A., Powell, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26834-3 · Cited by 245
Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies
Bar-Or, A., Pender, M. P., Khanna, R., Steinman, L., Hartung, H.-P., Maniar, T., Croze, E., Aftab, B. T., Giovannoni, G., & Joshi, M. A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.11.003 · Cited by 262
Self-citationAbbasi-Kangevari, M., Ghamari, S.-H., Safaeinejad, F., Bahrami, S., & Niknejad, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00238 · Cited by 79
“Nevertheless, there are uncertainties regarding the use of MSCs in MS treatment including tissue source, route of delivery, cell number, dosing, adverse effects, safety monitoring, and duration of action (8).”
Background
Metadata
- Authors
- Scolding, N. J., Pasquini, M., Reingold, S. C., Cohen, J. A., Sclerosis:, I. C. O. C.-B. T. F. M., Atkins, H., Banwell, B., Bar-Or, A., Bebo, B., Bowen, J., Burt, R., Calabresi, P., Cohen, J., Comi, G., Connick, P., Cross, A., Cutter, G., Derfuss, T., Ffrench-Constant, C., Freedman, M., Galipeau, J., Goldman, M., Goldman, S., Goodman, A., Green, A., Griffith, L., Hartung, H.-P., Hemmer, B., Hyun, I., Iacobaeus, E., Inglese, M., Jubelt, B., Karussis, D., Küry, P., Landsman, D., Laule, C., Liblau, R., Mancardi, G., Ann Marrie, R., Miller, A., Miller, R., Miller, D., Mowry, E., Muraro, P., Nash, R., Ontaneda, D., Pasquini, M., Pelletier, D., Peruzzotti-Jametti, L., Pluchino, S., Racke, M., Reingold, S., Rice, C., Ringdén, O., Rovira, A., Saccardi, R., Sadiq, S., Sarantopoulos, S., Savitz, S., Scolding, N., Soelberg Sorensen, P., Pia Sormani, M., Stuve, O., Tesar, P., Thompson, A., Trojano, M., Uccelli, A., Uitdehaag, B., Utz, U., Vukusic, S., Waubant, E., & Wilkins, A.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-07-21
- Volume
- 140
- Issue
- 11
- Pages
- 2776-2796
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2185110053
- Cited by
- 170
- References
- 19
- FWCI
- 16.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.